Ludivine Zoute
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ludivine Zoute.
Journal of Organic Chemistry | 2009
Gérald Lemonnier; Ludivine Zoute; Georges Dupas; Jean-Charles Quirion; Philippe Jubault
A efficient methodology allowing the one-pot stereoselective synthesis of alpha-fluoroacrylates, based on the addition of ethyl dibromofluoroacetate to a carbonyl derivative using diethylzinc as organometallic mediator, is described. Two different pathways have been identified depending on the involved carbonyl partner. In the case of aldehydes, an E2-type mechanism has been identified, whereas ketones go through an E1cb-type mechanism.
Bioorganic & Medicinal Chemistry | 2018
Hamid R. Hoveyda; Graeme Fraser; Ludivine Zoute; Guillaume Dutheuil; Didier Schils; Cyrille Evangelos Brantis; Alexey Lapin; Julien Parcq; Sandra Guitard; Francois Lenoir; Mohamed El Bousmaqui; Sarah Rorive; Sandrine Hospied; Sébastien Blanc; Jérôme Bernard; Frédéric Ooms; Joanne C. McNelis; Jerrold M. Olefsky
Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp3) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (ΔLLE = 0.3, ΔFsp3 = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.
Archive | 2009
Hamid R. Hoveyda; Cyrille Evangelos Brantis; Guillaume Dutheuil; Ludivine Zoute; Didier Schils; Jérôme Bernard
Archive | 2012
Hamid Hoveyda; Didier Schils; Ludivine Zoute; Julien Parcq
Archive | 2011
Hamid Hoveyda; Ludivine Zoute; Francois Lenoir
Archive | 2015
Hamid Hoveyda; Didier Schils; Ludivine Zoute; Julien Parcq; Jérôme Bernard; Graeme Fraser
Archive | 2010
Hamid Hoveyda; Cyrille Evangelos Brantis; Guillaume Dutheuil; Ludivine Zoute; Didier Schils; Graeme Fraser
Synthesis | 2006
Ludivine Zoute; Guillaume Dutheuil; Jean-Charles Quirion; Philippe Jubault; Xavier Pannecoucke
Archive | 2018
Hamid Hoveyda; Didier Schils; Ludivine Zoute; Julien Parcq
Archive | 2017
Didier Schils; Hamid Hoveyda; Julien Parcq; Ludivine Zoute